



## Tailor-made ADME-Tox

Admescope is a contract research organisation (CRO) providing the pharmaceutical industry with tailor-made ADME-Tox services to support the discovery and development of small molecules and biologics. Admescope serves customers globally, either as a standalone service or seamlessly integrated into the Symeres Medicinal Chemistry services.

Our services span over the whole ADME-Tox area, ranging from early screening assays to highly tailored and detailed studies. High quality data is ensured by optimising the conditions according to the compounds characteristics rather than using generic protocols. All data can be supplied with interpretation and context for the customer to help in understanding the real meaning of the numerical values and observations.

Our team of experts consists of chemists, biochemists, pharmacologists and technicians, all with long experience and strong expertise in ADMEstudies. Combination of our expertise and state-of-the-art instrumentation enables us to deliver high scientific and technical quality, always on time.

As part of **Symeres**, we aim to have real, positive impact on people's lives. We make molecules matter. Together.

## We offer:

- Integrated drug discovery services within the broader Symeres organization
- Tailored and optimised studies enabling high scientific & technical data quality
- World class expertise in drug metabolism, drug interactions, pharmacokinetics and quantitative bioanalysis
- Deep knowledge in analytical technologies (LC/MS and NMR)
- Continuous service development and adaptation of customers' processes
- Flexibility, high quality, fast turnaround and short response times





IN VITRO METABOLISM	<ul> <li>Metabolic stability</li> <li>Metabolite identification and profiling</li> <li>Identification of metabolising enzymes</li> <li>Non-CYP-mediated metabolism</li> <li>Extrahepatic metabolism</li> </ul>	<ul> <li>Metabolite production and NMR identification</li> <li>Reactive metabolite screening</li> <li>Acyl-glucuronide reactivity</li> <li>Stability in plasma, buffer or biorelevant media</li> <li>IVIVE</li> </ul>
IN VIVO DMPK	<ul> <li>Animal pharmacokinetics</li> <li>Metabolic identification <i>in vivo</i></li> <li>Metabolite profiling and characterisation in pre-clinical species</li> </ul>	
DRUG INTERACTIONS	<ul> <li>CYP inhibition</li> <li>UGT inhibition</li> <li>Inhibition towards other metabolising enzymes</li> </ul>	<ul> <li>CYP induction</li> <li>UGT induction</li> <li>Transporter interactions</li> <li>Custom <i>in vitro</i> interaction studies</li> </ul>
QUANTITATIVE BIOANALYSIS	<ul> <li>UHPLC/MS/MS, UHPLC/HR-MS, or UHPLC/r</li> <li>Plasma, urine, feces, brain homogenates &amp;</li> <li>Method development and validation</li> </ul>	adiodetection other tissue homogenates
PERMEABILITY AND TRANSPORTER	<ul> <li>Caco2 permeability</li> <li>Uptake and efflux transporters</li> <li>Cell monolayer and vesicle based assays</li> </ul>	
PHYSIOCHEMISTRY AND BINDING	<ul> <li>Lipophilicity (logD/P)</li> <li>Solubility</li> <li>Plasma protein binding</li> </ul>	<ul> <li>Red blood cell binding</li> <li>Tissue binding</li> <li>Microsome/hepatocyte binding</li> </ul>
IN VITRO TOXICOLOGY	<ul> <li>Cytotoxicity screening</li> <li>Genotoxicity screening</li> <li>Cardiotoxicity screening</li> <li>Mechanistic toxicity assays</li> </ul>	



- Protein MW and structural characterisation (LC/MS) •
- Peptide mapping and detection of post-translational modifications (LC/MS) •
- Quantification with LC/MS and ELISA
- Protein pharmacokinetics